TY - JOUR T1 - Onset of Inflammatory Eye Disease Under Tocilizumab Treatment for Rheumatologic Conditions: a Paradoxical Effect? JF - The Journal of Rheumatology JO - J Rheumatol SP - 2284 LP - 2284 DO - 10.3899/jrheum.110170 VL - 38 IS - 10 AU - DANIEL WENDLING AU - EMMANUELLE DERNIS AU - CLÉMENT PRATI AU - ERIC FRISCH AU - BERNARD DELBOSC Y1 - 2011/10/01 UR - http://www.jrheum.org/content/38/10/2284.abstract N2 - To the Editor:Tocilizumab (TCZ), a monoclonal antibody directed against interleukin 6 (IL-6) receptor, exerts powerful inhibition of IL-6 and demonstrates antiinflammatory properties. This biologic agent is used in chronic inflammatory diseases1. We describe 2 cases of onset of inflammatory eye disease under TCZ therapy. A 41-year-old man with defined axial HLA-B27-positive ankylosing spondylitis (AS, according to the modified New York criteria2) for 8 years was refractory to nonsteroidal antiinflammatory drugs, steroids, pamidronate, and 3 tumor necrosis factor (TNF) blockers (infliximab, etanercept, adalimumab). TCZ was initiated (8 mg/kg per month). Between the second and third infusion, a first episode of acute … Address correspondence to Prof. Wendling; E-mail: dwendling{at}chu-besancon.fr ER -